Becker's Healthcare January 28, 2019
The lack of transparency practiced by healthcare startups should leave investors concerned about another Theranos-style scandal, according to a recent report reviewed by TechCrunch.
Researchers associated with the Meta-Research Innovation Center at Stanford (Calif.) University evaluated the highest-valued healthcare startups — those worth at least $1 billion — against their published scientific literature. One of the report’s authors, John Ioannidis, MD, was one of the first people to identify issues with Theranos, namely that the startup participated in “stealth research.”
“Many years ago I was the first person to say that Theranos had a problem,” Dr. Ioannidis told TechCrunch. “The problem that I had then was that Theranos did not have any peer-reviewed evidence to show.”
Most of the highest-valued...
Today's Sponsors
Today's Sponsor